JOP20190045A1 - مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. - Google Patents

مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Info

Publication number
JOP20190045A1
JOP20190045A1 JOP/2019/0045A JOP20190045A JOP20190045A1 JO P20190045 A1 JOP20190045 A1 JO P20190045A1 JO P20190045 A JOP20190045 A JO P20190045A JO P20190045 A1 JOP20190045 A1 JO P20190045A1
Authority
JO
Jordan
Prior art keywords
substituted
naphthyridine
aryl
carboxylic acid
acid amides
Prior art date
Application number
JOP/2019/0045A
Other languages
English (en)
Inventor
Boultadakis Arapinis Melissa
Brechmann Markus
Vakalopoulos Alexandros
Mondritzki Thomas
Teller Henrik
Beat Wittwer Matthias
Andreas Kullmann Maximilian
Straub Alexander
Tinel Hanna
Freudenberger Till
Marquardt Tobias
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16188728.6A external-priority patent/EP3296298A1/de
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of JOP20190045A1 publication Critical patent/JOP20190045A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

يتعلق الاختراع الحالي بمركبات 1-aryl-naphthyridine-3-carboxylic acid amides مستبدلة في الموضع 7، وبطريقة لإنتاجها، وباستخدامها سواء لوحدها أو في توليفة في المعالجة و/أو الوقاية من أمراض واستخدامها لإنتاج أدوية للمعالجة و/أو الوقاية من أمراض، وبصورة خاصة للمعالجة و/أو الوقاية من الأمراض القلبية الوعائية وأمراض الكلى.
JOP/2019/0045A 2016-09-14 2017-06-16 مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. JOP20190045A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188728.6A EP3296298A1 (de) 2016-09-14 2016-09-14 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EP16202509 2016-12-06

Publications (1)

Publication Number Publication Date
JOP20190045A1 true JOP20190045A1 (ar) 2019-03-14

Family

ID=59966701

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0045A JOP20190045A1 (ar) 2016-09-14 2017-06-16 مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Country Status (40)

Country Link
US (3) US10927109B2 (ar)
EP (1) EP3512849B1 (ar)
JP (1) JP7295019B2 (ar)
KR (2) KR20190046851A (ar)
CN (4) CN115477649A (ar)
AU (1) AU2017326297B2 (ar)
BR (1) BR112019004982A2 (ar)
CA (1) CA3036497A1 (ar)
CL (1) CL2019000670A1 (ar)
CO (1) CO2019002361A2 (ar)
CR (1) CR20190131A (ar)
CU (1) CU24618B1 (ar)
CY (1) CY1124492T1 (ar)
DK (1) DK3512849T3 (ar)
DO (1) DOP2019000060A (ar)
EC (1) ECSP19018116A (ar)
ES (1) ES2887674T3 (ar)
GE (1) GEP20217332B (ar)
HR (1) HRP20211396T1 (ar)
HU (1) HUE056343T2 (ar)
IL (1) IL265106B (ar)
JO (1) JOP20190045A1 (ar)
LT (1) LT3512849T (ar)
MA (1) MA46235B1 (ar)
MX (1) MX2019003007A (ar)
MY (1) MY196473A (ar)
NI (1) NI201900023A (ar)
NZ (1) NZ751297A (ar)
PE (1) PE20190803A1 (ar)
PH (1) PH12019500535A1 (ar)
PL (1) PL3512849T3 (ar)
RS (1) RS62299B1 (ar)
SG (1) SG11201901973RA (ar)
SI (1) SI3512849T1 (ar)
TN (1) TN2019000083A1 (ar)
TW (1) TWI758325B (ar)
UA (1) UA125627C2 (ar)
UY (1) UY37403A (ar)
WO (1) WO2018050510A1 (ar)
ZA (1) ZA201902325B (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180016485A (ko) 2015-06-09 2018-02-14 바이엘 파마 악티엔게젤샤프트 무스카린성 m2 수용체의 양성 알로스테릭 조정제
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CA3179525A1 (en) * 2020-04-08 2021-10-14 Bayer Aktiengesellschaft Rapid detection of viral infection using rt-pcr

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
JPS60228479A (ja) 1984-04-26 1985-11-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE4301246A1 (de) 1993-01-19 1994-07-21 Bayer Ag Chinolon- und Naphthyridoncarbonsäurederivate
HU216803B (hu) * 1993-08-13 1999-08-30 Dong Wha Pharmaceutical Industrial Co., Ltd. Új kinolon-karbonsav-származékok
US6136823A (en) 1996-11-28 2000-10-24 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
JP2005511743A (ja) 2001-12-13 2005-04-28 ウォックハート・リミテッド 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
CN100471842C (zh) * 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
WO2005026165A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
KR20060123452A (ko) * 2003-12-09 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 나프티리딘 유도체 및 무스카린 수용체의 조절자로서의이의 용도
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
WO2010093341A1 (en) * 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US9199939B2 (en) 2009-12-17 2015-12-01 Merck Sharp & Dohme Corp. Quinoline amide M1 receptor positive allosteric modulators
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
BR112013000596A2 (pt) 2010-07-09 2019-09-24 Bayer Intelectual Property Gmbh piridinas e tiazinas fusionadas e seus usos.
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103360388B (zh) * 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
CN102964350A (zh) * 2012-09-20 2013-03-13 杨文� 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用
CN103183676B (zh) 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
HUE040696T2 (hu) 2014-11-03 2019-03-28 Bayer Pharma AG Hidroxialkil-szubsztituált feniltriazol-származékok és alkalmazásuk
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
MY194590A (en) 2015-06-09 2022-12-05 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
CN107820494B (zh) 2015-06-09 2020-10-16 艾伯维公司 核受体调节剂
KR20180016485A (ko) 2015-06-09 2018-02-14 바이엘 파마 악티엔게젤샤프트 무스카린성 m2 수용체의 양성 알로스테릭 조정제
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
MA46235A (fr) 2021-04-14
MA46235B1 (fr) 2021-10-29
UA125627C2 (uk) 2022-05-04
AU2017326297A1 (en) 2019-03-28
CN109689656B (zh) 2022-10-04
KR20190046851A (ko) 2019-05-07
CU20190020A7 (es) 2019-11-04
EP3512849A1 (de) 2019-07-24
AU2017326297B2 (en) 2021-07-29
CR20190131A (es) 2019-05-15
PE20190803A1 (es) 2019-06-10
EP3512849B1 (de) 2021-06-23
MX2019003007A (es) 2019-07-18
IL265106B (en) 2022-05-01
CO2019002361A2 (es) 2019-06-19
CN115429798A (zh) 2022-12-06
ECSP19018116A (es) 2019-03-29
TN2019000083A1 (en) 2020-07-15
US20210261541A1 (en) 2021-08-26
TW201811785A (zh) 2018-04-01
US11472803B2 (en) 2022-10-18
US20220089591A1 (en) 2022-03-24
CY1124492T1 (el) 2022-07-22
PH12019500535A1 (en) 2019-11-04
MY196473A (en) 2023-04-12
PL3512849T3 (pl) 2021-11-29
KR20230035437A (ko) 2023-03-13
US20190263805A1 (en) 2019-08-29
RS62299B1 (sr) 2021-09-30
TWI758325B (zh) 2022-03-21
HUE056343T2 (hu) 2022-02-28
DK3512849T3 (da) 2021-08-16
SG11201901973RA (en) 2019-04-29
WO2018050510A1 (de) 2018-03-22
CA3036497A1 (en) 2018-03-22
SI3512849T1 (sl) 2021-10-29
CN109689656A (zh) 2019-04-26
JP2019534320A (ja) 2019-11-28
CN115554294A (zh) 2023-01-03
CN115477649A (zh) 2022-12-16
NZ751297A (en) 2022-12-23
NI201900023A (es) 2019-05-23
CU24618B1 (es) 2022-08-09
HRP20211396T1 (hr) 2021-12-10
JP7295019B2 (ja) 2023-06-20
CL2019000670A1 (es) 2019-08-02
DOP2019000060A (es) 2019-04-15
US10927109B2 (en) 2021-02-23
ES2887674T3 (es) 2021-12-27
GEP20217332B (en) 2021-12-10
BR112019004982A2 (pt) 2019-08-20
UY37403A (es) 2018-04-30
LT3512849T (lt) 2021-08-25
ZA201902325B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
PH12015500106A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
PH12018500057A1 (en) Substituted oxopyridine derivatives
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12017502224A1 (en) Positive allosteric modulators of muscarinic md receptor
TN2015000370A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
MY169980A (en) Bisaryl-linked aryltriazolones and their use
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
TN2014000298A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
TN2016000107A1 (en) Substituted phenylalanine derivatives
MY196473A (en) 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof
JOP20200073A1 (ar) مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
TN2015000523A1 (en) Substituted benzoxazoles
UA113887C2 (xx) 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof